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Abstract
Aims Heart failure with mid-range ejection fraction (HFmrEF) has been proposed as a distinct HF phenotype, but whether
patients on this category fare worse, similarly, or better than those with HF with reduced EF (HFrEF) or preserved EF (HFpEF)
in terms of rehospitalization risks over time remains unclear.
Methods and results We prospectively included 2961 consecutive patients admitted for acute HF (AHF) in our institution. Of
them, 158 patients died during the index admission, leaving the sample size to be 2803 patients. Patients were categorized
according to their EF: HFrEF if EF ≤ 40% (n = 908, 32.4%); HFmrEF if EF = 41–49% (n = 449, 16.0%); and HFpEF if EF ≥ 50%
(n = 1446, 51.6%). Covariate-adjusted incidence rate ratios (IRRs) were used to evaluate the association between EF status
and recurrent all-cause and HF-related admissions. At a median follow-up of 2.6 years (inter-quartile range: 1.0–5.3), 1663
(59.3%) patients died, and 6035 all-cause readmissions were registered in 2026 patients (72.3%), 2163 of them HF related.
Rates of all-cause readmission per 100 patients-years of follow-up were 150.1, 176.9, and 163.6 in HFrEF, HFmrEF, and HFpEF,
respectively (P = 0.097). After multivariable adjustment, when compared with that of patients with HFrEF and HFpEF, HFmrEF
status was not significantly associated with a different risk of all-cause readmissions (IRR = 0.99; 95% confidence interval [CI],
0.77–1.27; P = 0.926; and IRR = 0.93; 95% CI, 0.74–1.18; P = 0.621, respectively) or HF-related readmissions (IRR = 1.06; 95% CI,
0.77–1.46; P = 0.725; and IRR = 1.11; 95% CI, 0.82–1.50; P = 0.511, respectively).
Conclusions Following an admission for AHF, patients with HFmrEF had a similar rehospitalization burden and a similar risk of
recurrent all-cause and HF-related admissions than had patients with HFrEF or HFpEF. Regarding morbidity risk, HFmrEF seems
not to be a distinct HF phenotype.
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Introduction
Rehospitalization burden in patients with heart failure (HF) re-
mains very high.1–3 These readmissions carry important and
negative consequences, being related to a poor quality of life
and an increased mortality risk, but also accounting for large
health care expenditures.1–3 Overall, readmission burden is
similar between patients with HF and reduced ejection frac-
tion (HFrEF) and patients with preserved ejection fraction
(HFpEF).4,5 The latest 2016 European Society of Cardiology
(ESC) HF Guidelines proposed a distinct category for patients
with an EF between 40% and 49%, which was HF with
mid-range EF (HFmrEF), calling for research to fill the knowl-
edge gaps regarding this new entity.1 Several studies have ad-
dressed the epidemiological, clinical, and prognostic
differences between HFmrEF and the classical phenotypes of
HF ever since, but results have varied considerably across dif-
ferent studies, and very few of them have focused on the mor-
bidity risk.6–16
Traditionally, the ‘time-to-first’ event approach has been
the classical method to evaluate the risk of adverse events
in HF, including readmission risks. However, in recent years,
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some experts have argued in favour of replacing classical
time-to-first analyses with recurrent event methodology.17–
19. This longitudinal approach would better quantify the hos-
pitalization burden over lifetime in a chronic disease such as
HF, and it is being increasingly adopted in recent years, as it
is the case of important recent clinical trials in HF, such as
the PARAGON-HF.20
In this study, we sought to evaluate the readmission bur-
den in patients with HFmrEF and to analyse whether patients
in this new category fare worse, similarly, or better in terms
of rehospitalization risks than do patients with HFrEF and
HFpEF, by means of a recurrent event analysis.
Methods
Study population
We prospectively include a cohort of 2961 consecutive pa-
tients admitted for acute HF in the cardiology department
of a tertiary teaching hospital (Hospital Clínico Universitario,
Valencia-Spain), from 2004 to 2017. Of them, 158 patients
died during the index admission, leaving the final sample size
to be 2803 patients. Patients with either new-onset or wors-
ening HF were included in the registry. A comprehensive set
of variables was routinely recorded at baseline using
pre-established registry questionnaires. Left ventricular EF
(LVEF) was assessed by two-dimensional transthoracic echo-
cardiogram in every patient during index hospitalization
(96 ± 24 h after admission). LVEF was calculated by the bi-
plane Simpson method. Three commercially available systems
were used throughout the study, Agilent Sonos 5500 ie33 and
EPIQ 7C (Philips, Massachusetts, USA). HF categories were
defined according to the 2016 HF ESC Guidelines: HFrEF
(EF < 40%), HFmrEF (EF = 41–49%), and HFpEF (EF ≥ 50%).
Treatment with angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, beta-blockers, aldosterone an-
tagonist, diuretics, and other therapeutic strategies were in-
dividualized by physicians’ criteria in clinical daily practice
according to established guidelines that were operating by
the time patients were included in the registry.
Follow-up and endpoints
The incidence of recurrent all-cause and HF-related
rehospitalizations during follow-up was selected as the pri-
mary endpoint. Only unplanned readmissions were included.
HF-related readmissions were those in which worsening or
acute HF was the main diagnosis at discharge. Hospitaliza-
tions were adjudicated based on the paper-written and elec-
tronic discharges records from every hospital in our health
care system. All-cause mortality was evaluated as a sensitivity
analysis. Researchers in charge of endpoints adjudications
were all blinded to the HF category.
Ethical concerns
The study was prospectively designed, conformed to the prin-
ciples outlined in the 1975 Declaration of Helsinki, and ap-
proved by the institutional local review ethics committee.
All patients gave informed consent.
Statistical analysis
Continuous variables were expressed as mean ± standard
deviation (SD) or median (inter-quartile range), whenever
appropriate. Discrete variables were summarized as per-
centages. Baseline continuous variables were compared
across HF categories with ANOVA, adopting Kruskal–Wallis
test for non-parametric variables. A descriptive analysis of
recurrent events was performed by counting the number
of hospitalizations during the entire follow-up. Crude inci-
dence rates (expressed as number of readmissions per
100 person-years) were calculated for each readmission
endpoint across HF categories. The following aspects were
important on how to analyse the data: (i) a concern about
informative censoring in HF, meaning that an increase in
readmission risks would lead to an associated increase in
the risk of subsequent death; and (ii) patient’s follow-up
is usually truncated at death as a terminal event, preclud-
ing new hospitalizations and potentially introducing bias re-
garding recurrent event analyses. To overcome these
pitfalls, we used bivariate negative binomial regression
(NBreg) models that simultaneously model the number of
readmissions (as counts) and mortality (as terminal event).
Regression estimates for both outcomes are mutually ad-
justed by means of shared frailty (accounting for the posi-
tive correlation between the two outcomes).21
Completeness of follow-up was calculated with the Clark
or completeness index C (92.5%). The independent associa-
tion between HFmrEF and recurrent hospitalizations was
assessed with either HFrEF or HFpEF as reference catego-
ries. Estimates of risk were expressed as incidence rate ra-
tios (IRRs). All variables listed in Table 1 were evaluated as
potential covariates in the NBreg models, independently of
their P value. A backward stepwise selection, with a P value
of 0.157 (Akaike information criterion) for variable inclu-
sion, was used to achieve parsimonious models and pre-
vent model’s overfitting.22,23 The covariates included in
the multivariable clinical models were as follows: age, sex,
no prior HF admission, Charlson co-morbidity index, heart
rate at admission, systolic blood pressure at admission,
blood urea nitrogen, haemoglobin, New York Heart Associ-
ation (NYHA) functional class prior at admission, treatment
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with beta-blockers, treatment with mineral receptor antag-
onists, and the N-terminal pro-brain natriuretic peptide
(NT-proBNP). All the covariates included in the model were
100% complete except for Charlson index, prior NYHA class,
and NT-proBNP, that were available in 2785 (98.1%), 2751
(98.1%), and 2612 (93.2%) of the cases. In these cases,
we performed a multiple imputation, avoiding dropping
such cases.
A two-sided P value of <0.05 was considered to be statis-
tically significant for all analyses. All survival analyses were
performed using STATA 15.1 (StataCorp. 2015. Stata Statisti-
cal Software: Release 14.1. College Station, TX: StataCorp
LP). The ‘Bivcnto’ Stata module was used in the multivariable
regression models for bivariate count outcomes.
Results
Baseline characteristics
Mean age of the cohort was 73.6 ± 11.1 years, 1381 (49%)
were women and 1293 (46%) had been previously admitted
for acute HF. The distribution of the cohort across HF catego-
ries was as follows: HFrEF, n = 908 (32.4%); HFmrEF, n = 449
(16.0%); and HFpEF, n = 1446 (51.6%). Table 1 summarizes
baseline characteristics stratified by the HF category accord-
ing to EF status. Overall, patients with HFmrEF had mostly
an intermediate clinical profile when compared to patients
with HFrEF or HFpEF. For instance, age, prevalence of female
sex, atrial fibrillation, echocardiographic signs of right
Table 1 Baseline characteristics in heart failure patients stratified according to ejection fraction
HFrEF (n = 908) HFmrEF (n = 449) HFpEF (n = 1446) P value
Demographics
Age, years 70 ± 12 75 ± 10 76 ± 10 <0.001
Female, n (%) 273 (30.1) 176 (39.2) 932 (64.4) <0.001
Medical history
Prior NYHA class III–IV, n (%) 138 (15.2) 74 (16.5) 229 (15,8) 0.556
No prior HF admission, n (%) 481 (53.0) 223 (49.7) 806 (53.9) 0.063
Hypertension, n (%) 657 (72.4) 377 (83.9) 1168 (80.8) <0.001
Diabetes mellitus, n (%) 400 (44.1) 236 (52.6) 612 (42.3) <0.001
Current smoker, n (%) 175 (19.3) 63 (14.0) 105 (7.3) <0.001
Ischaemic heart disease, n (%) 407 (44.8) 203 (45.2) 383 (26.5) <0.001
ICD carrier, n (%) 60 (6.9%) 11 (2.3%) 5 (0.4%) <0.001
CCI > 2, n (%) 323 (35.6) 180 (40.1) 440 (30.4) <0.001
QRS > 120 ms, n (%) 384 (42.3) 176 (39.2) 323 (22.3) <0.001
Atrial fibrillation, n (%) 293 (32.3) 186 (41.4) 764 (52.8) <0.001
Vital signs at admission
Heart rate, b.p.m. 101 ± 26 99 ± 27 98 ± 30 0.042
Systolic blood pressure, mmHg 140 ± 31 150 ± 34 150 ± 33 <0.001
Diastolic blood pressure, mmHg 82 ± 19 84 ± 21 80 ± 19 <0.001
Echocardiography
LVEF, % 31.3 ± 6.3 44.9 ± 2.5 61.6 ± 7.4 <0.001
LV diastolic diameter, mm 63.0 ± 7.9 57.7 ± 8.1 49.9 ± 7.0 <0.001
Left atrium diameter, mm 44.0 ± 7.9 43.9 ± 8.4 43.9 ± 8.0 0.453
Deceleration time, ms 185 ± 55.6 209.4 ± 66.8 223.1 ± 58.5 <0.001
E/e′ ratio 18.7 ± 8.5 17.4 ± 7.2 18.5 ± 11.2 0.263
TAPSE, mm 17.6 ± 8.4 18.1 ± 3.0 19.5 ± 6.0 <0.001
PASP, mmHg 42.8 ± 10.2 45.0 ± 31.3 47.0 ± 16.0 <0.001
Laboratory
BUN, mg/dL 58.9 ± 31.6 61.3 ± 30.6 60.1 ± 30.5 0.377
Haemoglobin, g/dL 12.9 ± 1.9 12.7 ± 1.9 12.1 ± 1.9 <0.001
Sodium, mEq/L 138.5 ± 4.2 138.9 ± 4.3 138.4 ± 4.7 0.121
NT-proBNP, pg/mLa 5923 (8109) 5612 (7913) 3530 (5230) <0.001
Serum creatinine at admission, mg/dL 1.31 ± 0.6 1.36 ± 0.7 1.23 ± 0.6 <0.001
Treatment at discharge
Furosemide dose, mg 71.7 ± 43.5 69.5 ± 45.5 63.1 ± 43.1 <0.001
Beta-blockers, n (%) 691 (76.1) 316 (70.4) 937 (64.8) <0.001
ACEI or ARB, n (%) 668 (71.9) 298 (64.9) 917 (61.8) <0.001
MRA, n (%) 519 (54.2) 132 (27.9) 220 (14.3) <0.001
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blockers; b.p.m., beats per minute; BUN, blood urea nitro-
gen; CCI, Charlson co-morbidity index; E/e′, ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (e′);
HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart
failure with preserved ejection fraction; ICD, implantable cardiac defibrillator; LV, left ventricular; LVEF, left ventricular ejection fraction;
MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association
functional class; PASP, pulmonary artery systolic pressure; TAPSE, tricuspid annular plane systolic excursion.
Values are mean ± standard deviation or n (%).
aValues are median (inter-quartile range).
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ventricular systolic dysfunction or pulmonary hypertension,
NT-proBNP levels, or the use of HF medications were
in-between in HFmrEF when compared with the classical phe-
notypes. In some other clinical features, such as ischaemic
heart disease or renal dysfunction, HFmrEF patients resem-
bled more HFrEF. HFmrEF patients showed the highest prev-
alence of cardiovascular risk factors such as hypertension or
diabetes, and a high profile of co-morbidities, as expressed
with the Charlson co-morbidity index.
All-cause readmissions
At a median follow-up of 2.6 years (1.0–5.3), a cumulative to-
tal of 6035 all-cause readmissions were registered in 2026 pa-
tients (72.3%). Of note, 865 (42.7%) and 379 (18.7%) patients
were readmitted ≥3 or ≥5 times along the follow-up, respec-
tively. No significant differences in the crude incidence rates
of all-cause readmissions were found across HF categories
(P = 0.097). Rates per 100 person-years of follow-up for re-
current all-cause hospitalizations across HF categories are
shown in Figure 1. However, after multivariate adjustment,
and when compared with that in patients with either HFrEF
or HFpEF, HFmrEF status was not significantly associated with
a different risk of all-cause readmissions (IRR = 0.99: 95% con-
fidence interval [CI], 0.77–1.27; P = 0.926; and IRR = 0.93:
95% CI, 0.74–1.19; P = 0.578, respectively) (Figure 2). All the
IRRs for the different comparisons among the three HF cate-
gories are shown in Table 2. Interestingly, no differences
were observed in the risk of all-cause readmissions between
the two classical HF phenotypes (HFrEF vs. HFpEF, Table 2).
Heart failure-related readmissions
A cumulative total of 2245 readmissions were registered in
1144 patients (40.8%). Crude incidence rates of HF-related
readmissions per 100 person-years of follow-up are shown in
Figure 1. These rates were numerically slightly higher in
HFmrEF when compared with those in the other categories,
but these differences were not significant (P = 0.071). After
multivariable adjustment, estimates of risk remained unal-
tered. Thus, no significant differences were found in the risk
of recurrent HF-related hospitalizations in HFmrEF when com-
pared with either HFrEF or HFpEF (IRR = 1.06; 95% CI, 0.77–
1.46; P = 0.578; and IRR = 1.11; 95% CI, 0.82–1.50; P = 0.511,
respectively) (Figure 2). All the IRRs for the different compari-
sons among the three HF categories are shown in Table 2. In
addition, there were again no differences in the risk of HF
readmissions between HFrEF and HFpEF patients (Table 2).
All the covariates and their estimates in the multivariate
NBreg models for both hospitalizations endpoints are pre-
sented in Table 3.
All-cause mortality
A total of 1663 patients died (59.3%) in the follow-up. By
Kaplan–Meier analysis, patients with HFrEF showed the
highest risk of long-term all-cause mortality (Figure S1). How-
ever, following multivariate adjustment, no significant differ-
ences in the risk of death across HF categories were found
(HFmrEF vs. HFrEF: IRR = 0.96; 95% CI, 0.72–1.23; P = 0.779;
and HFpEF vs. HFrEF: IRR = 0.96; 95% CI, 0.75–1.23; P = 0.758).
Discussion
In this large single-centre registry, we found that all-cause re-
admission rates of HFmrEF patients were similar to those
seen in patients with HFrEF and HFpEF. Accordingly, HFmrEF
status, when compared with HFrEF or HFpEF, was not associ-
ated with a different risk of recurrent all-cause hospitaliza-
tions. With regard to HF-related readmissions, incidence
rates and the risk of HF-related recurrent events were also
comparable in the three HF categories.
A need for evaluating the risk of
rehospitalizations in heart failure with mid-range
ejection fraction
HFmrEF was officially launched as a distinct entity in the
2016 ESC HF Guidelines.1 One of the main objectives of this
new phenotype was to encourage research to better eluci-
date clinical characteristics, prognosis, and treatment for
patients with an EF between 41% and 49%. As
Figure 1 Crude incidence of all-cause and HF-related readmission rates in
patients with HFrEF, HFmrEF, and HFpEF. HFmrEF, heart failure with
mid-range ejection fraction; HFpEF, heart failure with preserved ejection
fraction; HFrEF, heart failure with reduced ejection fraction. Complete-
ness of follow-up, using Clark C index, was 92.5%.
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recommended in the Guidelines, many studies had ad-
dressed all these open issues ever since,6,7,9,11–16,24,25 but
the adoption of this new category has been
controversial.26,27 In addition, despite that many studies
have focused on the clinical profile or the mortality risk
of HFmrEF, none of them have primarily focused on
Table 2 Risk of all-cause and heart failure-related recurrent admissions in patients with heart failure with mid-range ejection fraction
when compared with those with heart failure with reduced ejection fraction and heart failure with preserved ejection fraction in the mul-
tivariate models
NBreg models IRR (95% CI) P value IRR (95% CI) P value
All-cause recurrent admissions
HFrEF as reference HFpEF as reference
HFmrEF 0.99 (0.77–1.27) 0.926 0.93 (0.74–1.19) 0.578
HFpEF/HFrEFa 1.06 (0.85–1.32) 0.621 0.95 (0–76-1.18) 0.621
Heart failure-related recurrent admissions
HFrEF as reference HFpEF as reference
HFmrEF 1.06 (0.77–1.46) 0.578 1.11 (0.82–1.50) 0.511
HFpEF/HFrEFa 0.96 (0.72–1.27) 0.761 1.04 (0.79–1.38) 0.761
CI, confidence interval; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; HFpEF,
heart failure with preserved ejection fraction; IRR, incidence rate ratio; NBreg, negative binomial regression.
aHFpEF vs. HFrEF and HFrEF vs. HFpEF, as indicated.
Table 3 All the covariates and their estimates in the multivariate negative binomial regression models for all-cause and heart
failure-related recurrent admissions
IRR (CI 95%) P value IRR (CI 95%) P value
All-cause recurrent admissions HF-related recurrent admissions
Age 1.03 (1.02–1.04) <0.001 1.04 (1.03–1.05) <0.001
Male sex 1.25 (1.05–1.50) 0.013 1.03 (0.82–1.30) 0.770
No prior HF admission 0.55 (0.47–0.66) <0.001 0.13 (0.10–0.16) <0.001
Charlson index 1.16 (1.10–1.22) <0.001 1.12 (1.10–1.25) <0.001
SBP 0.99 (0.99–0.99) <0.001 0.99 (0.99–0.99) 0.001
Heart rate 0.99 (0.99–1.00) 0.126 0.99 (0.99–1.00) 0.148
Haemoglobin (g/dL) 0.92 (0.88–0.96) <0.001 0.92 (0.87–0.98) 0.006
BUN (g/dL) 1.00 (0.99–1.00) 0.119 1.00 (0.99–1.00) 0.156
Serum sodium 0.99 (0.96–0.99) 0.007 0.96 (0.94–0.98) 0.001
NT-proBNP (pg/mL) 1.00 (1.00–1.01) 0.002 1.00 (1.00–1.01) 0.002
Prior NYHA class 1.23 (1.08–1.39) 0.001 1.13 (0.96–1.33) 0.138
Beta-blockers 0.81 (0.68–0.97) 0.020 0.82 (0.66–1.03) 0.089
MRA 0.83 (0.69–1.01) 0.072 0.86 (0.67–1.11) 0.252
BUN, blood urea nitrogen; CI, confidence interval; HF, heart failure; IRR, incidence rate ratio; MRA, mineralocorticoid receptor antagonist;
NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure.
Figure 2 Risk of recurrent all-cause and HF-related hospitalizations in HFmrEF when compared with HFrEF or HFpEF in the multivariable regression
models for bivariate count outcomes. HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction;
HFrEF, heart failure with reduced ejection fraction.
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readmission risks. 6,7,9,11–16,24,25 Overall, prior studies on re-
admission risks in HFmrEF have shown conflicting results.
For instance, two meta-analyses assessing the prognosis in
HFmrEF were published in 2018.7,11 In the meta-analysis
by Altaie and Khalife, the risk of an HF-related readmission
was similar in HFmrEF when compared with that in HFpEF
or HFrEF.11 On the contrary, Lauritsen et al. reported that
the risk of an HF rehospitalization was lower in HFmrEF
than in HFrEF but was significantly higher than in HFpEF.7
Nowadays, hospitalizations in HF are a matter of great in-
terest. Hospital admissions are increasing worldwide, affect-
ing patients’ quality of life and increasing the risk of further
adverse events.1–3 In this context, further research into re-
hospitalization burden in HFmrEF seemed to be
appropriate.
Risk of readmission in heart failure with
mid-range ejection fraction: a distinct
phenotype?
As previously stated, prior studies have reported somewhat
conflicting results in HFmrEF. In data from the ‘Get with the
Guidelines’ registry, Shah et al. reported that patients with
HFmrEF had slightly higher readmission rates than patients
with HFpEF, whereas HF readmissions rates were intermedi-
ate between the two classical phenotypes.14 On the contrary,
survival free of all-cause and HF readmissions was similar re-
gardless of EF in the Trial of Intensified versus standard Med-
ical Therapy in Elderly patients with Congestive Heart Failure
(TIME-CHF),13 and along the same line, no differences were
found in the incidence of HF readmissions across the three
HF categories in a multicentre national cohort of 1241 pa-
tients discharged from acute HF in Spain,24 in concordance
with our results.
It is important to highlight that in all of these previous
studies, readmission risks have been evaluated as a time-
to-first event. Although this methodology is well recog-
nized, it probably does not accurately reflect the hospitali-
zation burden in HF. Nowadays, in order to capture the
morbidity burden following an admission for acute HF in
a more comprehensive way, some experts recommend to
evaluate every readmission that occur during follow-up, be-
cause recurrent events are the typical feature of HF disease
progression.17–19 The only study in which morbidity risk of
HFmrEF patients has been reported according to this meth-
odology has been conducted by Lund et al. on patients in-
cluded in the Candesartan in Heart Failure: Assessment of
Reduction in Mortality and Morbidity (CHARM)
programme.25 Patients with LVEF = 40–49%, when com-
pared with HFpEF patients, showed a non-significant trend
to a higher risk of recurrent HF admissions. Such an analy-
sis was not conducted for all-cause rehospitalizations, in
which, by a time-to-first analysis, it was somewhat
surprising that HFmrEF status was associated with the low-
est risk of readmission. CHARM included stable HF patients,
whereas our patients were included following an admission
for acute HF in ‘real-world’ clinical daily practice. In our co-
hort, HFmrEF patients were considerably older and showed
a higher prevalence of co-morbidities than those from
CHARM. Along this line, in the ESC-HF Long-Term (ESC-HF-
LT) registry, the incidence of all-cause and HF readmissions
was also much lower in HFmrEF than in HFrEF.9 These data
had a deep impact on the results from the meta-analysis of
Lauritsen et al., resulting in a lower risk of HF readmissions
in HFmrEF than in HFrEF.7 As in CHARM, patients included
in the ESC-HF-LT were stable, were relatively young, and
showed a lower prevalence of co-morbidities than did pa-
tients included in our registry (e.g. diabetes: 32.3% vs.
52.5%; atrial fibrillation: 18.3% vs. 41.7%, respectively).
Conversely, patients in both the TIME-CHF trial and the
study by Gómez-Otero were more similar to our
cohort,13,24 resulting in similar readmission risks in the
three HF categories. We believe that such differences in
the clinical profile of the patients may help to explain the
different outcomes across studies and the conflicting results
of previous meta-analyses.
HFmrEF is a heterogeneous and controversial category. It
has been stated that many patients in this category are in-
deed in transition from one classical HF phenotype to the
other, mostly from HFrEF to the so-called HF with improved
or recovered EF.28–30 We hypothesize that the clinical pro-
file of patients with HFmrEF may be different depending
on the clinical scenario. This ‘transitional’ HFmrEF pheno-
type may be more dominant in stable HF cohorts than in
patients admitted for acute HF. For instance, 34.8% pa-
tients with an LVEF = 40–49% from the ESC-HF-LT registry
were implantable cardiac defibrillator carriers.9 The labelling
of those patients with improved EF as HFmrEF may intro-
duce significant bias, as patients with improved EF are a
low-risk cohort,28,29 and this could help to explain the low-
est risk attributed to HFmrEF in some of the previous
studies.
In summary, our findings confirm the prohibitive burden of
hospitalizations following an episode of acute HF regardless
LVEF status. HFmrEF seems not to be a distinct phenotype
with regard to readmission risks. In our opinion, we should
move forward, leaving back the LVEF-centric way of evaluat-
ing the HF-associated morbidity. There is an unmet need for
reducing the readmission burden in every HF patient, beyond
their LVEF status.
Limitations
There are some limitations of our study that need to be ac-
knowledged. First, this is a single-centre observational study
in which hidden bias might be operating. Second, data on
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LVEF prior to the index episode are scarce and preclude us to
state definite conclusions on the percentage of patients with
HF and improved EF in our cohort. In addition, longitudinal
assessment of LVEF was out of the scope of the present
study, so transitional changes in HF categories during the
follow-up were not evaluated. Fourth, we did not focus on
any specific rehospitalization clustering in the follow-up.
Finally, the adoption of recurrent event methodology in the
HF field is relatively new, so there might be areas still sub-
jected to controversy. However, it seems to portray a more
accurate evaluation of the morbidity burden than the tradi-
tional time-to-first event endpoints.
Conclusions
Following an admission for acute HF, patients with HFmrEF
had a similar risk of recurrent all-cause and HF-related
hospitalizations than had patients with either HFrEF or HFpEF.
Further works aiming to unravel whether patients with
HFmrEF exhibit crucial pathophysiological, clinical, or thera-




Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Figure S1. Kaplan–Meier all-cause mortality curves according
to left ventricular ejection fraction. HFmrEF: heart failure with
mid-range ejection fraction; HFpEF: heart failure with pre-
served ejection fraction; HFrEF: heart failure with reduced
ejection fraction.
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